July 22 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP ANNOUNCES SUCCESSFUL MEETING WITH FDA ON PHASE III DESIGN IN NON-SMALL CELL LUNG CANCER
- IMMUTEP ANNOUNCES SUCCESSFUL MEETING WITH FDA ON PHASE III DESIGN IN NON-SMALL CELL LUNG CANCER
- IMMUTEP LTD: TACTI-004 REGISTRATIONAL TRIAL WILL ENROL ABOUT 750 PATIENTS REGARDLESS OF PD-L1 EXPRESSION
News: IMM Immutep Announces Successful Meeting With FDA On TACTI-004 Phase III Trial Design
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.015(4.48%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.8¢ | 31.5¢ | $1.587M | 4.950M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 35998 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 286931 | 7 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |